Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of DNL104 in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of DNL104 in Healthy Subjects

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DNL104 (Primary)
  • Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Neurodegenerative disorders
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Denali Therapeutics Inc

    • Most Recent Events

    • 22 Aug 2019 Results published in the Clinical Pharmacology and Therapeutics
    • 19 Mar 2018 According to a Denali 10-K Sec filing report 2018, this phase I trial of DNL104 (a former RIPK1 inhibitor product candidate) was initiated in Sep 2016 and was subsequently discontinued in Apr 2017, based on liver function test abnormalities in some clinical trial healthy volunteer participants.
    • 03 May 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top